🇺🇸 FDA
Patent

US 12227763

Methods and compositions for treating cancer

granted A61KA61K2039/505A61K2039/804

Quick answer

US patent 12227763 (Methods and compositions for treating cancer) held by CRISPR THERAPEUTICS AG expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/804, A61K2039/852, A61K2039/86